ELOXATIN® (oxaliplatin injection)-BASED CHEMOTHERAPY SETS NEW TREATMENT BENCHMARK IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Contacts :Salah Mahyaoui+ 33 6 73 68 78 88Anne Bancillon+ 33 6 86 31 03 89ELOXATIN® (oxaliplatin injection)-BASED CHEMOTHERAPY SETS NEW TREATMENT BENCHMARK IN PATIENTSWITH METASTATIC COLORECTAL CANCER- FOLFOX4 Chemotherapy Results in Improved Long-term [Five-years] Overall Survival for these Seriously Ill Patients -Paris, France, June 4, 2007 – FOLFOX4, an Eloxatin-based chemotherapy regimen, provided significant improvements in long-term [five-years] overall survival (OS) and time to disease progression (TTP) - a longer period of stable disease - in patients with metastatic